WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.074
Volume 7, Issue 11, 1-16. Research Article ISSN 2277– 7105

LIGAND BASE PHARMACOPHORE MODELING VRTUAL SCREENING AND DOCKING AGAINST TGFRB1 GENE MUTATION IN BREAST CANCER.

Kanwal Mushtaq[1]*, Zohaib Bashir[1], Hanif Khan[2], Wadeed ul Janan[2], Syed Faheem Askari[3] and Hussain Ali[4]

[1]Department of Bioinformatics, Government Post Graduate College Mandian, Pakistan.

[2]Department of Bioinformatics, Hazara University Dhodial Mansehra, Pakistan.

[3]GC University, Faisalabad, Pakistan.

[4]Govt Post Graduate Collge Mandain, Abbottabad, Pakistan.

Article Received on
04 April 2018,

Revised on 25 April 2018,
Accepted on 15 May 2018,

DOI: 10.20959/wjpr201811-12076

***Corresponding Author**
Kanwal Mushtaq
Department of Bioinformatics, Government Post Graduate College Mandian, Pakistan.

ABSTRACT

Introduction: The term "breast cancer" refers to a malignant tumor that has developed from cells in the breast. The types of cells that most commonly give rise to breast cancers are the milk-secreting cells and duct cells, which drain milk from the lobules to the nipple. Factors which add to the burden of breast cancer are the increase in obesity, alcohol consumption, inactivity, and hormone replacement therapy (HRT). **Methods**: In this research work ligand base pharmacophore modeling have been done against TGFRB1. The compound that are used against breast cancer were downloaded. Compounds were divided into active and experimental sets and pharmachophore model were generated. The shared feature pharmacophore model based on the pharmacophore model was developed. Virtual screening was performed against the shared features pharmacophore model to identify best drug compounds. The identified drug compounds docked with the mutated protein of the gene. **Results**: The Pharmacohpoere model displayed hydrogen bond donors, hydrogen bond acceptors, aromatic rings, Ionizable positive atoms, In total, 7 compounds were obtained similar to the shared feature pharmacophore model, and docked with the mutated protein. Only one ligand demonstrated best docking results, fulfills all the properties of Lipinski rule of five, non-toxic in nature. In the docked complex the common interactive amino acids identified are His A: 43, Val A: 34, Tyr A: 75, Lys1A:84, which confirmed the validity of a ligand molecule to be used as a drug in the treatment of breast

cancer. **Conclusion:** From Lipinski rule analysis and docking results it is suggested that the ligand can be used as a drug against breast cancer. This research work can be further utilized in laboratory settings to determine its adequacy.

KEYWORDS: Molecular Docking, Pharmacophore, TGFRB1, Toxic, Ligand.

INTRODUCTION

All the more powerful anticancer medication generation with novel modes about activity may be today's necessity. Oncologists are mindful of the truth that new medication disclosure must focus the Creating instrument from claiming tumor in place with move forward those restorative effectiveness. Numerous interpretation managing proteins are themselves deregulated for cancellous toward the level of statement alternately action (Noureen, Kalsoom, and Rashid 2010). Breast tumor will be third heading reason for passing to entirety overall. Each year, 1. 3 million new instances from claiming breast tumor need aid diagnosed worldwide, What's more represent Practically 15% for the greater part cancer-related passings. In the united States, those amount from claiming breast tumor situations is anticipated Metabolites 2015, 5 102 on expand each year, and therefore, this disease, Around other cancers, postures a noteworthy load to health awareness and the economy (Anaya-Ruiz and Perez-Santos 2015). Breast tumor remains a real open wellbeing issue. Currently, around every last bit cancers, breast tumor will be the practically basic disease previously, ladies over both created Furthermore creating nations. As stated by GLOBOCAN estimates, more than half (52. 9%) about 1. 67 million new breast tumor instances were diagnosed On creating nations done 2012 (Shajahan-Haq, Cheema, and Clarke 2015). Those Growth figure TGF-β1, its receptor TGFBR1, the TGF-β tying proteins LTBP1/2, the TGF-β-releasing thrombospondin 1 (THBS1), the negative effector SkiL, and the smad-associated atom SARA were upregulated for RA SFBs contrasted with OA SFBs, while TGF-β2 might have been downregulated. Upregulation about TGF-β1 what's more THBS1 mrna (both emphatically corresponded with clinical markers about ailment activity/severity) Furthermore downregulation about TGF-β2 mrna Previously, RA SFBs were affirmed Eventually Tom's perusing qPCR (Pohlers et al. 2007). Subsequently, transformations in both TGFBR2 Also TGFBR1 (TGF-β sort i receptor) were portrayed on make connected with promptly onset and Forceful thoracic aortic illness for MFS-like skeletal features, as well as hypertelorism, craniosynostosis, developmental delay, congenital fissure and bifid uvula, intrinsic coronary illness and aneurysms, Also dissections All around the blood vessel tree with denoted blood

vessel tortuosity; this state might have been termed Loeys-Dietz syndrome (LDS) (Jondeau et al. 2016). Those transforming Growth figure beta (TGF-b) superfamily, which incorporates activins, bone morphogenetic proteins (BMPs), TGF-bs, Growth Furthermore separation Components (GDFs), and different related factors, manages different cell division courses for example, such that proliferation, differentiation, growth, adhesion, What's more apoptosis, clinched alongside species extending starting with flies What's more nematodes should mammals. These discharged Growth elements transduce signs through an evolutionarily saved system directing, including kind i and kind ii serine/ threonine kinase receptors on the Mobile surface. Previously, mossycup oak cases, TGF-b ligand dimers launch the indicating course by tying to two sort ii receptors, which after that initiate two kind i receptors, What's more phosphorylate their trademark GS (glycine-serine coupled repeat) motifs, to structure an dynamic receptor indicating complex including both sorts for receptors and the ligand dimer. Those actuated sort i receptors propagate the sign from the Mobile surface of the cytoplasm, through the trans phosphorylation for Smad proteins which after that enter the core on control the interpretation from claiming focus genes. Those actuation of the kind i receptors will be viewed concerning illustration those national occasion in the era for signs by TGFbs (Cox et al. 2007). Transforming development figure beta 1 (TGFB1) might go about as a tumor silencer Toward mediating Growth capture through those CDK inhibitors p15INK4B or p21CIP1 Furthermore Eventually Tom's perusing hindering those outflow about c-Myc, CDK4, Also CDC25A. Paradoxically, tumor units bring been indicated should overexpress TGFB1. This overexpression will be thought with actuate angiogenesis and additionally outflow for endothelial Growth factor, prompting cell burgeoning and movement What's more permitting tumor phones on escape from those safe framework (Guo et al. 2012).

Pharmacophore methodologies need turned a standout amongst the major devices for medication regardless revelation then afterward days gone by century’s advancement. Different ligand-based What's more structure-based techniques bring been formed to enhanced pharmacophore demonstrating Furthermore have been effectively and extensively connected Previously, virtual screening, de novo plan Furthermore lead optimization (Yang 2010). Pharmacophores need aid utilized Likewise queries to recouping probable heads from structural databases for outlining atoms for particular fancied qualities What's more to assessing comparability What's more mixed bag from claiming particles control pharmacophore fingerprints. It might be used to adjust particles dependent upon the 3d course of action for concoction structures alternately to enhance prognostic 3d quantitative structural

action association (QSAR) models (Munir, Azam, and Mehmood 2016). To current consider created those ligand based pharmocophore for those TGFBR1 inhibitor. Similarly, Virtual screening may be a computational methodology utilized in the zones for medication regardless disclosure What's more improvement will investigate libraries from claiming little ligands which might make bag certain with their focus proteins alternately proteins same time docking will be a wonder about foreseeing the orientations about particles in the limited stable perplexing. To date, there need little data ahead 3D-QSAR Furthermore pharmacophore investigations of TGFB R1 inhibitors. Herein, we tend will report card those machine of pharmacophore modeling, virtual screening also atomic docking to TGFBR1 inhibitors. This ponder might have been embraced with figure it out intuitions under sub-atomic components Furthermore structural necessities vital for possibility restraint about TGFBR1. That might a chance to be supportive inside the outline about novel TGFBR1 inhibitors.

MATERIALS AND METHOD

The methodology used in this work is shown in Figure 1.

Drugs identification on the bases of activity

Following screening breast tumor inflicting genes those TBFGR1 gene might have been chosen from gene cards database (Rebhan et al. 1998). Done Look into collaborator to structural Bioinformatics, protein information bank (RCSB PDB) for refinement filters, those living being might have been chose Concerning illustration homo Sapiens, scientific classification Likewise Eukaryota only, test strategy might have been chose Similarly as X-beam crystallography for a X-beam resulotion from claiming 2. 0-2. 5 Å, which come about just TBFGR1_HUMAN proteins, around the individuals protein ids named concerning illustration 4x2f, were downloaded. RCSB PDB is essentially an database that holds X-beam crystallographic What's more atomic attractive full 3d structures for proteins What's more nucleic acids (Berman 2008). A discriminating boundary with entrance under structure-based virtual screening may be those absence of a suitable, simple should entry database from claiming purchasable mixes. We have In this manner ready a library from claiming 727 842 molecules, every with 3d structure, utilizing catalogs about exacerbates starting with vendors (the size from claiming this library proceeds should grow). The particles have been doled out naturally pertinent protonation states and would annotated with properties for example, such that sub-atomic weight, ascertained LogP, Also number of rotatable bonds. A Web-based

inquiry device around incorporating a atomic drawing interface empowers those database on be searched Furthermore browsed Furthermore subsets should a chance to be made. Then afterward that the TBFGR1 protein hold numerous mixes which we investigate through zinc database (Irwin and Shoichet 2005).



Figure 1: The method applied to design a pharmacophore model for TGFBR1 mutations in breast cancer.

Select active and non-active compound

Now selected the eight not active compound from the structure and selected 4 drugs which are used to cure the treatment of breast cancer. After that selected the structures were imported into LigandScout software and the protein preparation wizard was used structural alignment of proteins, to confirm structural correctness of the protein structures with high sureness structures. The associated protein structure was further reserved for the docking and pharmacophore analysis (Wolber and Langer 2001, 2005).

Ligand based Pharmcophore generation

The pharmacophoric features of every ligand were check in LigandScout software package and their shared feature pharmacophore as calculated. Ligandscout is an associated automatic Pharmacophore Model Creation package. The resulted shared feature pharmacophore contains the functional groups intricate in their bioactivity to targeted proteins.

Shared feature Pharmocophore

The shared feature pharmacophore model was distributed into an alignment tab of LigandScout and set as a reference; virtual screening was done against shared feature pharmacophore to obtain hit compounds, comparable to shared feature pharmacophore in the Zinc database with the support of Ligscree Server (Wolber and Langer 2001, 2005).

Virtual screening

The hit compounds acquired were then check for Lipinski rule of five. Lipinski rule of five conditions that drug-like compound must have HBD less than 5, HBA less than 10, molecular weight no more than 500 Da and logP ranges between 0-5 (Lipinski, 2004).

Docking

The compounds satisfying Lipinski rule of five were docked with wild-type and mutated shared feature TFBRG1 protein by the patch dock server. Patch dock is usually an algorithmic program utilized for molecular docking, geared near finding docking conversions and produce smooth molecular shapes (Schneidman-duhovny et al. 2005). Docking results were examined and compared with discovery studio; the pharmacophore models of hit compounds were organized in LigandScout software.

Pharmocophore generation for best docked Ligand

The ligand which are coming through pharmocophore docked with protein and visualize its properties and characteristics.

RESULTS AND DISCUSSION

Wild-type TGFBR1 protein ligand binding domain comprises of aggregate 503 amino corrosive buildup and made out of A chains.TGFBR1 protein comprises of 503 amino acids and comprises of just a single chain A. The wild-type protein were chosen to analyze the impacts of pharmacophore models on the ordinary proteins. Pharmacophore investigation is estimated as a fundamental segment of medication outline. The pharmacophore produced by LigandScout for the chose proteins informational index of bosom malignancy indicated three primary highlights Hydrogen bond acceptor (HBA), Hydrogen bond giver (HBD) and fragrant rings (AR). In each pharmacophore model of chose proteins the red bolts speak to Hydrogen bond acceptor, green bolt speaks to Hydrogen bond contributor and yellow circles speak to a sweet-smelling ring. Various prohibited volumes were likewise created in the models to show the space adjusting. The model contain hydrogen bond acceptors, hydrogen

bond contributors, and fragrant rings. The delegate pharmacophores of 4x2f protein are appeared in Figure 2.



Figure 2: Three-dimensional structure of TGFBR1 protein along with ligands.

Ligand was connected to wild-type TFGBR1 protein. We chose 8 in dynamic mixes from the protein structure and takes 4 dynamic medications which are utilized to cure bosom disease these days. Eight in dynamic compound which we chose from the protein appears in Figure 3. Four dynamic compound shows in Figure 4. Pharmacophore models of chose protein informational indexes were adjusted together based on structure, to create a common component pharmacophore appeared in Figure 5. The hit mixes were then checked for Lipinski govern of five just five mixes were satisfying every one of the principles of Lipinski, i.e., atomic weight<500 Da, HBD<5, HBA<10 and logP between 0-5. The hit mixes which satisfied Lipinski manage of five are appeared in Table 1.




H
HBA
HBA
HBA
H
HBA
OH
AR
H
O
S
HBA
HO
HBA
HBA
HBD
HBA
H


AR
H
H
H
O
PI
AR
HBA
H
AR
H


O
HBA
O
HBA
H


H
H
HBA
HBA
N
N
N
N
N
AR
AR
HBA
HBA
AR



Figure 3: structure feature of un active compounds.





Figure 4: structure feature of active compounds.

Molecular docking is a key apparatus in the structure molecular science and the computer drug design supported medication plan. The point of ligand-protein docking is to anticipate the primary restricting methods of a ligand with a known 3D structure of protein. The pharmacophore models of these compunds indicates one new compound superlative hit docked with protein structures were created in LigandScout to get data about HBD, HBA and ARs. The pharmacophore models of these compound and structure highlight of entire ligand are appeared in Figure 5. All fulfilled compound were docked with transformed shared element TGFBR1 protein and wild-type TGFBR1 protein, in each docked complex the normal collaborating amino corrosive buildups were same as that of pharmacophore models,

however among the mixes spoke to in Table 1, the first and fourth compound created more than five knocks with the two proteins in the wake of docking. Bumps allude to the crash of particles to each other; the minimum number of bumps is five.



Figure 5: Shared feature of whole ligands and new compound used as inhibitor in breast cancer.

The one compounds demonstrated ideal docking results with wild type shared feature TGFBR1 protein structures. The one compounds with best docking results are shown in Figure 4.

Compounds	H Donors	H acceptor	Molecular Weight
ZINC5323007	2	3	327
ZINC53230080	2	3	327
ZINC53229419	2	3	473
ZINC53229421	2	3	473
ZINC53298528	2	3	368
ZINC53298531	2	3	368
ZINC53298579	2	3	457
ZINC53298580	2	3	457

Table 1: Lipinski of five rule for following compounds

Compound represented in Figure 5 demonstrated better interactions with interacting amino residues and best fit in the pockets of protein. In both the wild-type protein dockings, similar bondings were observed, whereas, in wild-type docked complex some extra bondings were also observed that determine the stability of hit compounds to better use as drugs. The docking results and interacting amino acid residues for wild type shared feature protein are shown in Figure 2. All these one compounds are best suitable to use as drugs as they fulfill all the properties of Lipinski's rule so they will demonstrate fewer side effects as compared to the drugs available in the market. It is suggested that this compounds can be used in the treatment of TGFBR1 gene in breast cancer.

The amino acid His A: 43, Val A: 34, Tyr A: 75, Lys1A:84 are bind to ligand molecule and no bumps will seen. This compound will docked in the pocket of desired receptor. The 2d and 3d ligand protein attraction are shown in figure 6 in which this ligand attach and bind to this protein.





Figure 6: 2D and 3D interaction of ligand with receptor protein.

DISCUSSION

Those pharmacophore model will be a helpful device around to new lead exacerbates identification and modeling. Pharmacophore feature is the to start with step towards seeing those coordinated effort between a receptor What's more a ligand. It might have been frequently all the recommended similarly as the "spirit" of the structure-activity majority of the data enlarged to date. An pharmacophore model may be An sensible qualitative prediction of tying Eventually Tom's perusing identikit the three-dimensional plan from claiming little amount iotas belongs on practical aggregations (Haseeb et al., 2014]. Two basic methodologies utilized within pharmacophore demonstrating are ligand based and organized based. Ligand-based pharmacophore demonstrating adjusts those superposition of a set of animated mixes What's more extracting imparted concoction features fundamental to the bioactivity about atom whiles structure built pharmacophore demonstrating adjusts the instrument for looking at guaranteeing connections between receptor and ligand (Sheng,2010). In this Scrutinize worth of effort structure based pharmacophore demonstrating methodology might have been used. The combinations of the pharmacophore, virtual screening, Also atomic docking positively provide for workable inhibitors that might bring limitless impact for Different test investigations done illnesses (Kandakatla and Ramakrishnan 2014). The compound Characteristics from claiming mixes ran across toward those association are taken under translation under those structure-based models, and also those associations the middle of the target receptor and the ligand atom (Zhang, Wang, and Qiao 2013). These pharmacophore models may a chance to be functional with think about those inhibitory movements; What's more to future explorations for novel medication regardless mixes to breast tumor.

CONCLUSION

The display fill in might have been done on discover novel inhibitors about TGFBR1 by the on silico method, which particularly ties with its dynamic site. Comprehension of the key essential ligand qualities for TGFBR1 restraint need been finished Eventually Tom's perusing applying ligand-based pharmacophore model configuration, virtual screening, and Furthermore sub-atomic docking methodologies. The use of 3d structures about mutated TGFBR1 proteins need revealed a pharmacophore model demonstrating those magic features fundamental to inhibitor tying. Those generated pharmacophore holds three essential features; HBD, HBA Also ar. Done future, these pharmacophore models will aid will find new antitumor compounds, gotten possibility inhibitors might a chance to be bought Furthermore tried in vitro against those TGFBR1 What's more different growth borealis lines, on test its sufficiency What's more social advantage. Further test strategies could be directed with focus those viability for these pharmacophore models as inhibitor compound.

ACKNOWLEDGMENT

Authors seriously acknowledge the sustenance delivered by the Department of Bioinformatics and Bioinformatics research club Government Post Graduate College Mandian for conducting this research work. The authors also thanks to Professor Ghulam Rasool, Anum Munir, Shumaila Azam, Sajid Khan and faculty of bioinformatics, and friends who's encourage us**.**

REFERENCES

1. Ã, Christopher A. Lipinski. “Lead Profiling Lead- and Drug-like Compounds : The Rule-of-Five Revolution.” 2004; 337–41.
2. Anaya-Ruiz, Maricruz and Martin Perez-Santos. “Innovation Status of Gene Therapy for Breast Cancer.” *Asian Pacific Journal of Cancer Prevention : APJCP* 2015; 16(9): 4133–36. Retrieved (http://www.ncbi.nlm.nih.gov/pubmed/25987099).
3. Berman, Helen M. “The Protein Data Bank: A Historical Perspective.” *Acta Crystallographica Section A: Foundations of Crystallography* 2008; 64(1): 88–95.
4. Cox, David G., Kathryn Penney, Qun Guo, Susan E. Hankinson, and David J. Hunter. “TGFB1 and TGFBR1 Polymorphisms and Breast Cancer Risk in the Nurses’ Health Study.” *BMC Cancer* 2007; 7: 1–6.
5. Guo, Huihui et al. “Molecular Characterization of TGF-β Type I Receptor Gene (Tgfbr1) in Chlamys Farreri, and the Association of Allelic Variants with Growth Traits.” *PLoS*

ONE 2012; 7(11).

6. Irwin, John J. and Brian K. Shoichet. "ZINC - A Free Database of Commercially Available Compounds for Virtual Screening." *Journal of Chemical Information and Modeling*, 2005; 45(1): 177–82.
7. Jondeau, Guillaume et al. "International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium)." *Circulation: Cardiovascular Genetics*, 2016; 9(6): 548–58.
8. Kandakatla, N. and G. Ramakrishnan. "Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors." *Adv Bioinformatics* 2014; 812148. Retrieved (http://www.ncbi.nlm.nih.gov/pubmed/25525429).
9. Munir, Anum, Shumaila Azam, and Azhar Mehmood. "Structure-Based Pharmacophore Modeling, Virtual Screening and Molecular Docking for the Treatment of ESR1 Mutations in Breast Cancer." *Drug Designing: Open Access*, 2016; 05(03): 1–10. Retrieved (https://www.omicsgroup.org/journals/structurebased-pharmacophore-modeling-virtual-screening-andmolecular-docking-for-the-treatment-of-esr1-mutations-in-breast-cancer-2169-0138-1000137.php?aid=82519).
10. Noureen, Nighat, Saima Kalsoom, and Hamid Rashid. "Ligand Based Pharmacophore Modelling of Anticancer Histone Deacetylase Inhibitors." *African Journal of Biotechnology*, 2010; 9(25): 3923–31.
11. Pohlers, Dirk et al. "Constitutive Upregulation of the Transforming Growth Factor-β Pathway in Rheumatoid Arthritis Synovial Fibroblasts." *Arthritis Research & Therapy* Retrieved (http://arthritis-research.biomedcentral.com/articles/10.1186/ar2217)., 2007; 9(3): R59.
12. Rebhan, Michael, Vered Chalifa-Caspi, Jaime Prilusky, and Doron Lancet. "GeneCards: A Novel Functional Genomics Compendium with Automated Data Mining and Query Reformulation Support." *Bioinformatics*, 1998; 14(8): 656–64.
13. Schneidman-duhovny, Dina, Yuval Inbar, Ruth Nussinov, and Haim J. Wolfson. "PatchDock and SymmDock : Servers for Rigid and Symmetric Docking." 2005; 33: 363–67.
14. Shajahan-Haq, Ayesha N., Mehar S. Cheema, and Robert Clarke. "Application of Metabolomics in Drug Resistant Breast Cancer Research." *Metabolites*, 2015; 5(1): 100–118.
15. View, Drug Repositioning. "LIGAND BASED PHARMACOPHORE DEVELOPMENT FOR COLORECTAL CANCER." (January)., 2016.

16. Wolber, G. and T. Langer. 2001. "LigandScout : Automated Pharmacophore Model Creation." *Bioinformatics* 6020.
17. Wolber, Gerhard and Thierry Langer. "LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters." *Journal of Chemical Information and Modeling*, 2005; 45(1): 160–69.
18. Yang, Sheng-Yong. "Pharmacophore Modeling and Applications in Drug Discovery: Challenges and Recent Advances." *Drug Discovery Today* 2010; 15(11-12): 444–50. Retrieved (http://linkinghub.elsevier.com/retrieve/pii/S135964461000111X).
19. Zhang, Yanling, Yuanming Wang, and Yanjiang. Qiao. "Structure-Based Pharmacophore Models Generation and Combinatorial Screening of ICE Inhibitors." *Applied Mechanics and Materials* 347-350(Instruments, Measurement, Electronics and Information Engineering): 2013; 1216–20, 6.